Q-omics provides the consensus-scored AGMO profile across patient tissues and cancer cell-line models. AGMO expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AGMO is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, AGMO RNA expression shows 15,525 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KICH, and THYM as cancer lineages where AGMO shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AGMO — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AGMO survival associations across molecular data types. AGMO RNA expression shows survival associations in the most cancer types (28), followed by mutation status (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AGMO RNA expression–survival associations across cancer types. High AGMO expression shows unfavorable associations in ACC, STAD, UCEC, PAAD and COAD, but favorable associations in KIRC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AGMO RNA expression.
This table summarizes AGMO tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for AGMO. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AGMO shows lower tumor expression in KICH, THCA, BRCA and CHOL and higher tumor expression in KIRC and LUAD. The KICH box plot shows higher AGMO RNA expression in normal versus tumor tissue (log2 FC = −2.166, t-test p < 0.001).
This table shows molecular features associated with AGMO in patient tissues and cancer cell lines. In patient samples, AGMO shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, AGMO RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and SKIN.
